Subscribe To
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 – – Phase 1 clinical trial for IL-12 INDUKINE WTX-330 progressing in patients with advanced or metastatic solid tumors or lymphoma – WATERTOWN, Mass., Aug. […] The post Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update appeared first on F...
Read More
Posted: Aug 10 2023, 11:10
Author Name: forextv
Views: 112292